CCEL
NASDAQCryo-Cell International Inc.
Price$3.59+0.16 (+4.66%)
2026-01-162026-04-22
News · 26 weeks150%
2025-10-262026-04-19
Mix690d
- SEC Filings3(50%)
- Other2(33%)
- Earnings1(17%)
Latest news
25 items- SECSEC Form 10-Q filed by Cryo-Cell International Inc.10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial ResultsCryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million in processing and storage fee revenue, $36,000 in product revenue and approximately $1,400 in public banking revenue compared to $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately
- SECCryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCryo-Cell Receives NYSE American Continued Listing NoticeCryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30,
- SECSEC Form 10-K filed by Cryo-Cell International Inc.10-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo
- INSIDERSEC Form 4 filed by Chairman, Co-CEO Portnoy David4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Co-CEO Portnoy Mark L.4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Chief Information Officer Mikulinsky Oleg4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by VP Finance, CFO Taymans Jill M4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 2,445 shares, increasing direct ownership by 0.13% to 847,629 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 3,990 shares, increasing direct ownership by 0.47% to 846,540 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David was granted 5,540 shares, increasing direct ownership by 0.66% to 842,550 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Other Events8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERChairman, Co-CEO Portnoy David was granted 9,666 shares, increasing direct ownership by 1% to 837,010 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERSEC Form 4 filed by Director Mizrahi Daniel4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERSEC Form 4 filed by Director Berger Harold D.4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECSEC Form 10-Q filed by Cryo-Cell International Inc.10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- PRCord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial ResultsCryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company", "Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net income for the three months ended August 31, 2025 of $749,000, or $0.09 per basic share and diluted share, compared to net income of $1.05 million, or $0.13 per basic and diluted share for the three months ended August 31,
- SECSEC Form DEF 14A filed by Cryo-Cell International Inc.DEF 14A - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERChairman, Co-CEO Portnoy David bought $76,486 worth of shares (17,175 units at $4.45), increasing direct ownership by 2% to 827,344 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- INSIDERChairman, Co-CEO Portnoy David bought $189,986 worth of shares (42,900 units at $4.43), increasing direct ownership by 0.89% to 811,920 units (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
- SECCryo-Cell International Inc. filed SEC Form 8-K: Other Events8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
- INSIDERChairman, Co-CEO Portnoy David disposed of 15,611 shares (SEC Form 4)4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)